17.55
-0.65 (-3.57%)
| Penutupan Terdahulu | 18.20 |
| Buka | 17.66 |
| Jumlah Dagangan | 1,352,086 |
| Purata Dagangan (3B) | 1,060,347 |
| Modal Pasaran | 1,956,579,200 |
| Harga / Jualan (P/S) | 3.03 |
| Harga / Buku (P/B) | 5.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Apr 2025 |
| Margin Keuntungan | -26.41% |
| Margin Operasi (TTM) | -24.43% |
| EPS Cair (TTM) | -1.51 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 192.49% |
| Nisbah Semasa (MRQ) | 1.47 |
| Aliran Tunai Operasi (OCF TTM) | -30.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 16.94 M |
| Pulangan Atas Aset (ROA TTM) | -8.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Menurun | Bercampur |
| Medical Devices (Global) | Menurun | Menurun | |
| Stok | NovoCure Limited | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.87% |
| % Dimiliki oleh Institusi | 87.40% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 34.00 (Piper Sandler, 93.73%) | Beli |
| Median | 28.00 (59.54%) | |
| Rendah | 27.00 (Wedbush, 53.85%) | Pegang |
| Purata | 29.67 (69.06%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 16.32 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 27 Jun 2025 | 34.00 (93.73%) | Beli | 17.06 |
| 23 Apr 2025 | 34.00 (93.73%) | Beli | 17.77 | |
| Wedbush | 16 Apr 2025 | 27.00 (53.85%) | Pegang | 15.83 |
| JP Morgan | 10 Apr 2025 | 28.00 (59.54%) | Pegang | 16.08 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 30 Jun 2025 | Pengumuman | Novocure to Report Second Quarter 2025 Financial Results |
| 31 May 2025 | Pengumuman | Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting |
| 24 Apr 2025 | Pengumuman | Novocure Reports First Quarter 2025 Financial Results |
| 23 Apr 2025 | Pengumuman | Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting |
| 22 Apr 2025 | Pengumuman | Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer |
| 01 Apr 2025 | Pengumuman | Novocure to Report First Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |